---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-023593"
form_type: "8-K"
ticker: "NUWE"
cik: "0001506492"
company_name: "Nuwellis, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:56:40.421149+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nuwellis Q1 revenue down 5% to $1.8M; net loss widens to $6.5M

## Summary
- Revenue $1.8M, 5% decline from $1.9M in Q1 2022; gross margin improved 120 bps to 58.4%.
- Heart Failure segment revenue up 21% YoY; Pediatrics down 28%, Critical Care down 4%.
- Net loss $6.5M ($5.76 loss per share) vs $4.5M ($42.45 loss per share) in prior year; includes $755K non-cash warrant revaluation expense.
- Cash, equivalents and marketable securities $12.1M at March 31, 2023; no debt.
- CEO cites new clinical evidence driving heart failure growth; focused on making Aquadex ultrafiltration therapy standard of care.

## SEC filing metadata
- accession: 0001140361-23-023593
- form_type: 8-K
- ticker: NUWE
- cik: 0001506492
- company_name: Nuwellis, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506492/000114036123023593/0001140361-23-023593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506492/000114036123023593/brhc20052638_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-023593
- JSON: https://secwatch.observer/filing/0001140361-23-023593.json
- Plain text: https://secwatch.observer/filing/0001140361-23-023593.txt

## Key facts
- Earnings Releases
  Nuwellis, Inc. reported the first quarter ended March 31, 2023 results: revenue $1.8 million, net income $6.5 million, EPS a loss of $5.76 per basic and diluted common share.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $1.8 million
  - Net income: $6.5 million
  - EPS: a loss of $5.76 per basic and diluted common share
  - Result: reported results
  source text: technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2023. • Revenue of $1.8 million for the first quarter 2023, a 5% decrease over the prior-year period. • By segment, first quarter 2023 revenue in Heart Failure increased approximately 21% over the same period
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506492/000114036123023593/0001140361-23-023593-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.